{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:18:37Z","timestamp":1790216317234,"version":"4.1.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jaad.2022.10.001","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T21:09:33Z","timestamp":1665436173000},"page":"751-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Skin disorders and interstitial lung disease: Part I\u2014Screening, diagnosis, and therapeutic principles"],"prefix":"10.1016","volume":"88","author":[{"given":"Melika","family":"Motamedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Yacyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Abril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Netchiporouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2022.10.001_bib1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society international multidisciplinary Consensus classification of the idiopathic interstitial pneumonias","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib85","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.rcl.2016.05.005","article-title":"Imaging of pulmonary manifestations of connective tissue diseases","volume":"54","author":"Ahuja","year":"2016","journal-title":"Radiol Clin North Am"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib87","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/2397198319894851","article-title":"Circulating biomarkers of systemic sclerosis \u2013 interstitial lung disease","volume":"5","author":"Hoffmann-Vold","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.001_bib88","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"40","author":"Long","year":"2019","journal-title":"Clin Chest Med"},{"issue":"7","key":"10.1016\/j.jaad.2022.10.001_bib89","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00296-018-3991-7","article-title":"Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review","volume":"38","author":"Gonz\u00e1lez-Moreno","year":"2018","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.jaad.2022.10.001_bib90","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib91","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/modpathol.2010.65","article-title":"The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome","volume":"23","author":"Yousem","year":"2010","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib92","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2177\/jsci.39.150","article-title":"Anti-EJ antibody positive interstitial lung disease with skin changes at the\u00a0fingertips","volume":"39","author":"Ota","year":"2016","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib93","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2022.10.001_bib27","doi-asserted-by":"crossref","first-page":"h6819","DOI":"10.1136\/bmj.h6819","article-title":"Management of interstitial lung disease associated with connective tissue disease","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib94","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.rcl.2016.05.005","article-title":"Imaging of pulmonary manifestations of connective tissue diseases","volume":"54","author":"Ahuja","year":"2016","journal-title":"Radiol Clin North Am"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","article-title":"Associations between anti-Ro52 antibodies and lung fibrosis in mixed\u00a0connective tissue disease","volume":"55","author":"Gunnarsson","year":"2016","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib96","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.rcl.2016.05.005","article-title":"Imaging of pulmonary manifestations of connective tissue diseases","volume":"54","author":"Ahuja","year":"2016","journal-title":"Radiol Clin North Am"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib97","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-79-1-37","article-title":"Diffuse interstitial lung disease in systemic lupus erythematosus","volume":"79","author":"Eisenberg","year":"1973","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jaad.2022.10.001_bib98","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/anr.1780321007","article-title":"A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus","volume":"32","author":"Ward","year":"1989","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib99","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.chest.2017.11.030","article-title":"The pathogenesis of pulmonary sarcoidosis and implications for treatment","volume":"153","author":"Patterson","year":"2018","journal-title":"Chest"},{"issue":"Supplement_6","key":"10.1016\/j.jaad.2022.10.001_bib100","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1513\/AnnalsATS.201707-566OT","article-title":"High-risk sarcoidosis. Current concepts and Research imperatives","volume":"14","author":"Sauer","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaad.2022.10.001_bib101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir Med J"},{"issue":"12","key":"10.1016\/j.jaad.2022.10.001_bib103","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2165\/0002018-200831120-00008","article-title":"Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands","volume":"31","author":"Wijnen","year":"2008","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2022.10.001_bib104","first-page":"51","article-title":"Interstitial lung disease with ANCA-associated vasculitis","volume":"9","author":"Katsumata","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-021-01451-4","article-title":"Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"1-2","key":"10.1016\/j.jaad.2022.10.001_bib106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF02010633","article-title":"Chest x-ray findings in the acute phase of Kawasaki disease","volume":"20","author":"Umezawa","year":"1989","journal-title":"Pediatr Radiol"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib107","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ppul.23885","article-title":"Pulmonary presentation of Kawasaki disease-A diagnostic challenge","volume":"53","author":"Singh","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ppul.10333","article-title":"Inflammatory pulmonary nodules in Kawasaki disease","volume":"36","author":"Freeman","year":"2003","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.001_bib109","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1378\/chest.11-1241","article-title":"Interstitial pneumonia\u00a0associated with bullous pemphigoid","volume":"141","author":"Yoshioka","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000351427","article-title":"Interstitial pneumonia associated with linear immunoglobulin A\/immunoglobulin G bullous dermatosis","volume":"86","author":"Kakugawa","year":"2013","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib111","first-page":"725","article-title":"[A fatal case of pemphigus vulgaris with interstitial pneumonia occurring during gold therapy]","volume":"99","author":"Usuba","year":"1989","journal-title":"Nihon Hifuka Gakkai Zasshi"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib112","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/dth.12342","article-title":"Pemphigus vulgaris-associated interstitial lung disease","volume":"29","author":"Bai","year":"2016","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib113","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.crohns.2010.03.008","article-title":"Pulmonary\u00a0manifestations of inflammatory bowel disease: case presentations and review","volume":"4","author":"Basseri","year":"2010","journal-title":"J CrohnsColitis"},{"key":"10.1016\/j.jaad.2022.10.001_bib114","first-page":"A6334","article-title":"Pulmonary fibrosis and pyoderma gangrenosum: what's the common denominator?","volume":"199","author":"Shah","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4187\/respcare.07117","article-title":"Diffuse cystic lung diseases","volume":"65","author":"Obaidat","year":"2020","journal-title":"Respir Care"},{"issue":"5","key":"10.1016\/j.jaad.2022.10.001_bib116","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5603\/ARM.a2017.0046","article-title":"Pulmonary Langerhans' cell histiocytosis in adults","volume":"85","author":"Radzikowska","year":"2017","journal-title":"Adv Respir Med"},{"issue":"16","key":"10.1016\/j.jaad.2022.10.001_bib117","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1182\/blood.2019000933","article-title":"Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder","volume":"135","author":"Melani","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib118","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PAP.0b013e3181c6a524","article-title":"Histiocytic disorders of the lung","volume":"17","author":"Nagarjun Rao","year":"2010","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib119","doi-asserted-by":"crossref","first-page":"15","DOI":"10.29046\/TMF.016.1.014","article-title":"Sinus histiocytosis: an uncommon presentation of an uncommon condition","volume":"16","author":"Greco","year":"2015","journal-title":"Med Forum"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.001_bib120","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1620\/tjem.227.231","article-title":"Intrathoracic Rosai-Dorfman disease with spontaneous remission: a clinical report and a review of the literature","volume":"227","author":"Noguchi","year":"2012","journal-title":"Tohoku J Exp Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib121","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.prp.2005.11.005","article-title":"Iatrogenic Kaposi's sarcoma following steroid therapy for nonspecific interstitial pneumonia with HHV-8 genotyping","volume":"202","author":"Joo","year":"2006","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jaad.2022.10.001_bib122","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1172-4-18","article-title":"Pulmonary involvement in Kaposi sarcoma: correlation between imaging and pathology","volume":"4","author":"Gasparetto","year":"2009","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.jaad.2022.10.001_bib123","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/tropej\/fmx080","article-title":"Human Herpesvirus 8 in perinatally HIV-infected children with interstitial lung disease","volume":"64","author":"Scotta","year":"2018","journal-title":"J Trop Pediatr"},{"issue":"18","key":"10.1016\/j.jaad.2022.10.001_bib124","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2169\/internalmedicine.52.0112","article-title":"Immunoglobulin G4-related lung disease accompanied by organizing pneumonia","volume":"52","author":"Suzuki","year":"2013","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib125","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/rheumatology\/kex146","article-title":"More than meets the eye: IgG4-related disease presenting as isolated interstitial lung disease","volume":"56","author":"Jagpal","year":"2017","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib126","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4046\/trd.2014.77.2.85","article-title":"A case of IgG4-related lung disease presenting as interstitial lung disease","volume":"77","author":"Ahn","year":"2014","journal-title":"Tuberc Respir Dis"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib127","doi-asserted-by":"crossref","first-page":"588","DOI":"10.21037\/atm-20-2708","article-title":"Pulmonary light chain deposition disease: a case series and literature review","volume":"8","author":"Wei","year":"2020","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1183\/09031936.06.00044006","article-title":"Neurofibromatosis-associated lung disease: a case series and literature review","volume":"29","author":"Zamora","year":"2007","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib129","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1183\/13993003.00308-2016","article-title":"Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive","volume":"48","author":"Newton","year":"2016","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.jaad.2022.10.001_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17122111","article-title":"Lung involvement in children with hereditary autoinflammatory disorders","volume":"17","author":"Tarantino","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib131","article-title":"The VEXAS syndrome: uncontrolled inflammation and macrocytic anaemia in a 77-year-old male patient","volume":"8","author":"Himmelmann","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.jaad.2022.10.001_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.699126","article-title":"Editorial: interstitial lung disease in primary immunodeficiencies","volume":"12","author":"Fevang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2022.10.001_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627423","article-title":"Granulomatous lymphocytic interstitial lung disease (GLILD) in common\u00a0variable immunodeficiency (CVID): amulticenter retrospective study of patients from Italian PIDreferral centers","volume":"12","author":"Cinetto","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib134","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jaip.2017.01.021","article-title":"British Lung Foundation\/United Kingdom primary immunodeficiency network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders","volume":"5","author":"Hurst","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib3","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S2213-2600(21)00017-5","article-title":"Early\u00a0diagnosis\u00a0of\u00a0fibrotic interstitial lung disease: challenges\u00a0and opportunities","volume":"9","author":"Spagnolo","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaad.2022.10.001_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.751181","article-title":"Variability in global prevalence of interstitial lung disease","volume":"8","author":"Kaul","year":"2021","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.rmed.2003.10.015","article-title":"Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment","volume":"98","author":"Thomeer","year":"2004","journal-title":"Respir Med"},{"key":"10.1016\/j.jaad.2022.10.001_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.jaad.2022.10.001_bib7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.mayocp.2018.03.020","article-title":"Short telomere syndromes in clinical practice: bridging bench and bedside","volume":"93","author":"Mangaonkar","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"9807","key":"10.1016\/j.jaad.2022.10.001_bib8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"issue":"52","key":"10.1016\/j.jaad.2022.10.001_bib9","doi-asserted-by":"crossref","first-page":"E1475","DOI":"10.1073\/pnas.1117988108","article-title":"Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition","volume":"108","author":"Rock","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"35","key":"10.1016\/j.jaad.2022.10.001_bib10","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1073\/pnas.0605669103","article-title":"Alveolar epithelial cell mesenchymal transition develops in\u00a0vivo during pulmonary fibrosis and is regulated by the extracellular matrix","volume":"103","author":"Kim","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2022.10.001_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.737570","article-title":"Epithelial-to-mesenchymal transition in fibrosis: concepts and targeting strategies","volume":"12","author":"Lovisa","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.jaad.2022.10.001_bib12","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1084\/jem.20110551","article-title":"Integrating mechanisms of pulmonary fibrosis","volume":"208","author":"Wynn","year":"2011","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in\u00a0tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2022.10.001_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126211","article-title":"Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms","volume":"22","author":"Montero","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"2 Suppl","key":"10.1016\/j.jaad.2022.10.001_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/2397198320903867","article-title":"Pathogenesis of systemic sclerosis associated interstitial lung disease","volume":"5","author":"Nihtyanova","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12890-018-0660-2","article-title":"Risk factors for interstitial lung disease: a 9-year Nationwide population-based study","volume":"18","author":"Choi","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaad.2022.10.001_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.rmed.2017.10.021","article-title":"Clubbing in patients with fibrotic interstitial lung diseases","volume":"132","author":"van Manen","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib19","article-title":"Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study","volume":"8","author":"Moran-Mendoza","year":"2021","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib20","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.chest.2020.02.044","article-title":"Derivation and validation of a diagnostic prediction tool for interstitial lung disease","volume":"158","author":"Pugashetti","year":"2020","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMp048244","article-title":"The physical exam and the sense of smell","volume":"354","author":"Bomback","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.001_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1378\/chest.73.3.399","article-title":"The functional basis of pulmonary sounds","volume":"73","author":"Forgacs","year":"1978","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jaad.2022.10.001_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034428","article-title":"Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care","volume":"10","author":"Thickett","year":"2020","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib24","doi-asserted-by":"crossref","first-page":"102619","DOI":"10.1016\/j.autrev.2020.102619","article-title":"May capillaroscopy be a candidate tool in future algorithms for SSC-ILD: are we looking for the holy grail? A systematic review","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.001_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","article-title":"Management of systemic sclerosis-associated interstitial lung disease","volume":"31","author":"Roofeh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1183\/09031936.05.00021005","article-title":"Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity","volume":"26","author":"Cottin","year":"2005","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/art.39528","article-title":"Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension","volume":"68","author":"Antoniou","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","article-title":"Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies","volume":"52","author":"Bonifazi","year":"2013","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12931-021-01711-1","article-title":"Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management","volume":"22","author":"Luppi","year":"2021","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib32","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.mcg.0000225549.19127.90","article-title":"Esophageal disease in scleroderma","volume":"40","author":"Ebert","year":"2006","journal-title":"J Clin Gastroenterol"},{"issue":"31","key":"10.1016\/j.jaad.2022.10.001_bib33","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.3748\/wjg.v27.i31.5201","article-title":"Dysphagia, reflux and related sequelae due to altered physiology in scleroderma","volume":"27","author":"Kadakuntla","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"25","key":"10.1016\/j.jaad.2022.10.001_bib36","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2022.10.001_bib37","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic\u00a0high-resolution CT scan than placebo: findings\u00a0from the scleroderma lung study","volume":"136","author":"Goldin","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","article-title":"Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of scleroderma lung study II","volume":"151","author":"Tashkin","year":"2017","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jaad.2022.10.001_bib34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.10.001_bib40","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.jaad.2022.10.001_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"3","author":"Baughman","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.jaad.2022.10.001_bib44","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/art.1780261015","article-title":"Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis","volume":"26","author":"Cannon","year":"1983","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib45","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a\u00a0meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib46","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00296-020-04773-4","article-title":"Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review","volume":"41","author":"Dawson","year":"2021","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib47","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028501","article-title":"Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis","volume":"101","author":"Yu","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/rheumatology\/kep052","article-title":"Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis","volume":"48","author":"Sawada","year":"2009","journal-title":"Rheumatol"},{"issue":"21","key":"10.1016\/j.jaad.2022.10.001_bib49","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib50","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/ajrccm.158.1.9709089","article-title":"Colchicine versus\u00a0prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group","volume":"158","author":"Douglas","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.reuma.2011.11.006","article-title":"Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis?","volume":"8","author":"P\u00e9rez Campos","year":"2012","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.jaad.2022.10.001_bib54","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221117002","article-title":"Immunomodulatory treatment of interstitial lung disease","volume":"16","author":"van den Bosch","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"26","key":"10.1016\/j.jaad.2022.10.001_bib55","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.001_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00296-010-1697-6","article-title":"Corticosteroids and the risk of scleroderma renal crisis: a systematic review","volume":"32","author":"Trang","year":"2012","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.jaad.2022.10.001_bib57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MCP.0b013e3283483ea5","article-title":"Biological treatments and connective tissue disease associated interstitial lung disease","volume":"17","author":"Panopoulos","year":"2011","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-009-0931-6","article-title":"Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment","volume":"30","author":"Taki","year":"2009","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.jaad.2022.10.001_bib59","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology biologics register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib60","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pds.3409","article-title":"Association between\u00a0anti-TNF-\u03b1 therapy and interstitial lung disease","volume":"22","author":"Herrinton","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.jaad.2022.10.001_bib61","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.jaad.2022.10.001_bib62","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.001_bib63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience\u00a0with\u00a0rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2022.10.001_bib65","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-8-7","article-title":"Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease","volume":"10","author":"Vacchi","year":"2021","journal-title":"Drugs Context"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib66","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib67","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/acr.22589","article-title":"Treatment algorithms in systemic lupus erythematosus","volume":"67","author":"Muangchan","year":"2015","journal-title":"ArthritisCare Res"},{"key":"10.1016\/j.jaad.2022.10.001_bib68","article-title":"Rituximab-induced interstitial lung disease: five case reports","volume":"2","author":"Naqibullah","year":"2015","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.jaad.2022.10.001_bib69","doi-asserted-by":"crossref","first-page":"740","DOI":"10.5414\/CP203840","article-title":"Rituximab may cause higher mortality in young autoimmune disease patients with rituximab-induced interstitial lung disease: a case report and systematic review of the literature","volume":"58","author":"He","year":"2020","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.jaad.2022.10.001_bib70","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.001_bib71","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"issue":"21","key":"10.1016\/j.jaad.2022.10.001_bib72","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jaad.2022.10.001_bib73","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary\u00a0fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib74","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"18","key":"10.1016\/j.jaad.2022.10.001_bib75","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jaad.2022.10.001_bib76","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jaad.2022.10.001_bib77","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib78","first-page":"246","article-title":"Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases","volume":"21","author":"Godeau","year":"1994","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids\u2014clinical implication of primary prophylaxis using trimethoprim\u2013sulfamethoxazole","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.001_bib80","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","article-title":"Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study","volume":"16","author":"Katsuyama","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2022.10.001_bib81","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","article-title":"Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study","volume":"40","author":"Hsu","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2022.10.001_bib82","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/RHU.0000000000000731","article-title":"Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim\/sulfamethoxazole","volume":"24","author":"Yukawa","year":"2018","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.10.001_bib83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"15","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2022.10.001_bib84","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/03009742.2020.1850854","article-title":"Reduction of Pneumocystis jirovecii pneumonia and bloodstream infections by trimethoprim\u2013sulfamethoxazole prophylaxis in patients with rheumatic diseases","volume":"50","author":"Honda","year":"2021","journal-title":"Scand J Rheumatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222027967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222027967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:06:52Z","timestamp":1759273612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222027967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0190962222027967"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.10.001","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skin disorders and interstitial lung disease: Part I\u2014Screening, diagnosis, and therapeutic principles","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.09.051","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}